Clinicopathologic Significance of BRAF Mutation and Extracellular Signal Regulated Kinase 1/2 Expression in Patients With a Colorectal Adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyung Ook | - |
dc.contributor.author | Kim, Beom Gyu | - |
dc.contributor.author | Cha, Seong Jae | - |
dc.contributor.author | Park, Yong Gum | - |
dc.contributor.author | Lee, Tae Jin | - |
dc.date.available | 2019-03-08T17:58:17Z | - |
dc.date.issued | 2015-02 | - |
dc.identifier.issn | 2287-9714 | - |
dc.identifier.issn | 2287-9722 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9884 | - |
dc.description.abstract | Purpose: BRAF mutation and expression of extracellular signal regulated kinase (ERK) are linked with colorectal carcinogenesis through the serrated pathway. BRAF and ERK1/2 play important roles in the activation of mitogen-activated protein (MAP) kinase signaling pathways. The present study investigated the clinicopathologic outcomes of BRAF mutation and ERK1/2 expression in patients with colorectal cancer (CRC) and the possibility of using them as prognostic indicators. Methods: Dual-priming oligonucleotide-based multiplex polymerase chain reaction for BRAF(V600E) mutation and immunohistochemical analysis of ERK1/2 were performed using 65 formalin-fixed, paraffin-embedded samples from patients with CRC. We analyzed the dependences of the clinicopathologic features on BRAF mutation and ERK1/2 expression. Results: Out of 65 samples from CRC patients, BRAF mutation was detected in 3 (4.6%). The 3 patients with BRAF mutation presented with T3 CRC with lymph node metastasis (stage III) showing moderately or poorly differentiated histology. ERK1 and ERK2 were positively detected in 73.8% and 15.4% of the patients with CRC, respectively. ERK1 expression was significantly correlated with lymph node metastasis (P = 0.049). ERK2 expression was significantly correlated with tumor emboli (P < 0.05), tumor invasion (P = 0.035), lymph node metastasis (P = 0.017), and stage (P = 0.02). Conclusion: BRAF mutation and ERK1/2 expression may be associated with advanced or more aggressive CRC. These molecular markers might play prognostic roles in CRC developed through the serrated pathway. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC COLOPROCTOLOGY | - |
dc.title | Clinicopathologic Significance of BRAF Mutation and Extracellular Signal Regulated Kinase 1/2 Expression in Patients With a Colorectal Adenocarcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.3393/ac.2015.31.1.9 | - |
dc.identifier.bibliographicCitation | ANNALS OF COLOPROCTOLOGY, v.31, no.1, pp 9 - 15 | - |
dc.identifier.kciid | ART001965518 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000441690800005 | - |
dc.identifier.scopusid | 2-s2.0-84925879955 | - |
dc.citation.endPage | 15 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 9 | - |
dc.citation.title | ANNALS OF COLOPROCTOLOGY | - |
dc.citation.volume | 31 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | BRAF | - |
dc.subject.keywordAuthor | ERK1 | - |
dc.subject.keywordAuthor | ERK2 | - |
dc.subject.keywordAuthor | Colorectal neoplasms | - |
dc.subject.keywordAuthor | Adenocarcinoma | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.